Trial Profile
An Open-label Study to Evaluate the Effect of Combination Therapy With Epothilone D and Herceptin on Tumor Response in Patients With HER-2 Overexpressing Locally Advanced or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Epothilone D (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 17 Jul 2007 Status changed from in progress to completed.
- 15 Nov 2006 Status change
- 21 Oct 2006 New trial record.